Please login to Zacks.com or register to post a comment.
They're hand-picked from the list of Zacks Rank #1 Strong Buys. Our experts predict that their prices will jump the soonest.
Today, you can see them free.
| No Recent Quote currently available |
|
My Portfolio Tracker One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts. Set yours up today. |
Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.
Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.
Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.
My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.
| Company Name | Symbol | %Change |
|---|---|---|
| SCIENTIFIC L | SCIL | 8.00% |
| NATUS MEDICA | BABY | 6.11% |
| SUMMER INFAN | SUMR | 6.02% |
| RADIANT LOGI | RLGT | 5.32% |
| NEW ORIENTAL | EDU | 4.51% |
Please login to Zacks.com or register to post a comment.
Resources
Client Support
Zacks Research is Reported On:
Zacks Investment Research
is an A+ Rated BBB
Accredited Business.
Copyright 2013 Zacks Investment Research
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1986 it has nearly tripled the S&P 500 with an average gain of +26% per year. These returns cover a period from 1986-2011 and were examined and attested by Baker Tilly, an independent accounting firm.
Visit performance for information about the performance numbers displayed above.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This page is temporarily not available. Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext. 9339.
On January 9, 2013, we reaffirmed our long-term Neutral recommendation on Ameriprise Financial Inc. ( AMP - Analyst Report ) based on its consistent assets under management (AUM) growth and robust capital deployment actions. However, elevated expenses and unsettling macro-economic factors are expected to remain a drag on its profitability in the near to medium term. Moreover, this financial services company retains a Zacks Rank #3 (Hold).
Why the Neutral Stance?
We have maintained this stance since none of the estimates moved upwards over the last 60 days. In addition, over the past four quarters, Ameriprise has delivered two positive and two negative earnings surprises with an average surprise of negative 3.2%.
The company is expected to announce its fourth quarter 2012 results on January 30. The Zacks Consensus Estimate for the quarter is pegged at $1.49 per share on revenue expectation of $2,567 million. The company had delivered better-than-expected third-quarter earnings on the back of augmented top line and lower expenses.
Further, a well-diversified portfolio compared with its industry peers along with powerful capital deployment actions are the positives for the company. Also, growth through acquisitions has helped it expand significantly and better serve the dynamic markets. The recent and most notable acquisition is the asset management business of Columbia Management from Bank of America Corporation ( BAC - Analyst Report ) in 2010. This acquisition has significantly pushed up the performance of Ameriprise’s retail mutual fund and institutional management businesses.
However, escalating expenses remain a major headwind for the company. Higher distribution expenses, general and administrative expenses, elevated interest and debt expense as well as bank conversion expenditure are expected to further increase its expenses, putting the bottom line under pressure. In addition, existing low interest rate environment and the ongoing outflows related to the integration of Columbia Management will keep Ameriprise’s financials under pressure in the near term.
The earnings ESP (expected surprise prediction) – the percentage difference between the Most Accurate Estimate and the Zacks Consensus Estimate – for the company is 0.67%. This, coupled with its Zacks Rank of 3, indicates that the company will surely beat the Zacks Consensus Estimate.
Other Stocks to Consider
The other stocks in the banking sector that are performing well and are worth considering include AllianceBernstein Holding L.P. ( AB - Snapshot Report ) and Virtus Investment Partners, Inc. ( VRTS - Snapshot Report ) . Both of these companies carry a Zacks Rank #1 (Strong Buy).
Read the full reports :
Analyst Report on AMP
Analyst Report on BAC
Snapshot Report on AB
Snapshot Report on VRTS